Our study provides comprehensive evidence that ESR1, ESR2, and PGR are feasible prognostic markers and therapeutic targets for multiple cancers and that they could be a factor for disease prediction, disease evaluation, and individualized treatment in various types of cancer. Here, ESR1 is linked to cancer.